Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Space & Other Races

Philip Seo, MD, MHS  |  Issue: October 2020  |  October 19, 2020

Orpheus FX / shutterstock.com

Orpheus FX / shutterstock.com

On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics.

I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This group of scientists met to discuss all that was still not understood about the Earth. Together, they realized technology had finally reached the point at which important questions regarding planetary sciences could be tackled.

This meeting led to the International Geophysical Year, a multi-national scientific collaboration that would start on July 1, 1957, to coincide with peak sunspot activity, so scientists could examine the impact of solar activity on the Earth.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I know, I know. Stick with me.

The International Council of Scientific Unions spent seven years planning experiments that would be conducted by 67 countries in more than 4,000 research stations worldwide. The careful planning was warranted because the International Geophysical Year was intended to bring the Cold War to an end.

The years following the end of World War II were characterized by a lack of international scientific exchange, particularly between the U.S. and the Soviet Union. The International Geophysical Year was meant to break the ice and usher in a new era of international collaboration.

And then the politicians got involved.

In 1955, the U.S. had announced its intent to launch an artificial satellite, ostensibly to celebrate the International Geophysical Year. Not to be outdone, four days later, the Soviet Union announced that it, too, would launch an artificial satellite, also to honor the multi-national scientific collaboration. Unlike the U.S., however, the Soviet Union actually did it.

On Oct. 4, 1957, the Soviet Union launched Sputnik 1, the first man-made satellite to orbit the Earth. Four months later, the U.S. achieved the same landmark, but it was undeniable: the Soviet Union got there first.2

Don’t look now, but Sputnik has beaten us again.

On Aug. 11, 2020, President Vladimir Putin of Russia introduced the world to Sputnik V—not a satellite, but an adenovirus-based vaccine he proclaimed was the first effective defense against SARS-CoV-2. The Russian Health Ministry announced plans to start vaccinating health workers and teachers, followed by the general population, this fall. Millions of doses of the vaccine are being prepared, many of which have already been sold to other nations.3 Meanwhile, the closest competitors are still in clinical trials. What do we know about this vaccine, and more importantly, how did the Russians reach the finish line first?

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug UpdatesOpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19vaccines

Related Articles
    ACR Convergence 2020

    ACR Convergence 2020: Progress Toward COVID-19 Vaccines

    November 11, 2020

    ACR CONVERGENCE 2020—A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across…

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Anze Furlan / SHUTTERSTOCK.COM

    How Immunosuppression May Affect COVID-19 Vaccine Response

    June 13, 2021

    Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences